PSA Case Studies

Dr Jonny Coxon
Declarations of interest

I have received honoraria from:

• Prostate Cancer UK
• Besins
• Bayer
• Ferring
• Eli Lilly
2. How do you counsel pre test about the limitation sod this test
Case 1 – history

- 66 year-old male presents with increasingly bothersome LUTS:
  - voiding symptoms (slow flow, hesitancy)
  - storage symptoms (frequency & nocturia)
  - gradually worsening for 2-3 years
- Otherwise fit and well
Case 1 – examination

• Abdomen and external genitalia normal
• DRE: large smooth prostate (unable to reach top)
• Urine dip NAD
Case 1 – investigation

• Frequency volume chart:
  – total daily voided volume approx 2L
  – increased daytime frequency
  – nocturia 1-3x per night

• PSA 1.9

• IPSS 25 / 35
Case 1 – question

• What do you make of the PSA in this case?
Case 1 – management

• He has moderate to severe bothersome LUTS with a large prostate (i.e., >30g) and a PSA > 1.4

• NICE LUTS guideline would suggest consider combination therapy: α-blocker plus 5-ARI

• Review patient at 4-6 weeks (to check efficacy of alpha blocker), 3-6 months (to check efficacy of 5ARI) then every 6-12 months
Case 1 – learning point

• As well as use in prostate cancer risk, **PSA also a valuable indicator of the risk of progression**

• A prostate that feels large on examination, or where not possible to reach the upper pole with the examining finger is highly likely to be >30g
Case 2 – History

• A 57 year-old man presents with fairly new erectile dysfunction
• No other symptoms (no LUTS)
• Amongst other tests, would you consider a PSA (and DRE) to assess for prostate cancer?
Case 2 – Discussion

• Rather depends who you ask!
• If you ask NICE...
Suspected cancer: recognition and referral

NICE guideline
Published: 23 June 2015
nice.org.uk/guidance/ng12
1.6.2 Consider a prostate-specific antigen (PSA) test and digital rectal examination to assess for prostate cancer in men with:

- any lower urinary tract symptoms, such as nocturia, urinary frequency, hesitancy, urgency or retention or
- erectile dysfunction or
- visible haematuria. [new 2015]

1.6.3 Refer men using a suspected cancer pathway referral (for an appointment within 2 weeks) for prostate cancer if their PSA levels are above the age-specific reference range. [new 2015]

Controversial – to say the least!
Case 3 – History

• 54 year-old man with no relevant symptoms at all comes in and asks you for a PSA test
• Do you say he can have it?
• Do you say he should have it?
Guidance

Prostate cancer risk management programme: overview

From: Public Health England
First published: 1 January 2015
Last updated: 29 March 2016, see all updates

This document explains the Prostate Cancer Risk Management Programme (PCRMP), PSA testing and evidence against a national screening programme.

The NHS Prostate Cancer Risk Management Programme (PCRMP) provides GPs and primary care professionals with information to counsel asymptomatic men aged 50 and over who ask about prostate specific antigen (PSA) testing for prostate cancer.

The PCRMP, revised and updated in March 2016, includes:

- full evidence document for GPs
- summary information sheet for GPs
- summary information sheet for men aged 50 and over

NHS Choices also has further information that men may find helpful.

The PSA test measures the level of PSA in a man’s blood. It is the most common initial test for men who are worried about prostate cancer.
This Prostate Cancer Risk Management Programme (PCRMP) sheet helps GPs give clear and balanced information to asymptomatic men who ask about prostate specific antigen (PSA) testing. The PSA test is available free to any well man aged 50 and over who requests it.

GPs should use their clinical judgement to manage symptomatic men and those aged under 50 who are considered to have higher risk for prostate cancer.
ERSPC study

To prevent one PCa death, can look at values:

a) NNI: Number Needed to Invite
   - 9 yrs: 1410
   - 11 yrs: 979
   - 13 yrs: 781

b) NND: Number Needed to Diagnose:
   - 9 yrs: 48
   - 11 yrs: 35
   - 13 yrs: 27
Prostate cancer mortality

Nelson-Aalen cumulative hazard

Time since randomisation (years)
Gothenburg Study
Case 4 – History

• A 57 year-old man asked the HCA for a PSA to be added to his NHS health check blood tests
• Done. Result came back as 3.5
• What do you do?
Case 4 – Examination

- DRE: Normal texture, mildly enlarged smooth prostate gland
Case 4 – Management

• PSA of 3.5 – normal or not??

1.6.3 Refer men using a suspected cancer pathway referral (for an appointment within 2 weeks) for prostate cancer if their PSA levels are above the age-specific reference range. [new 2015]
Case 4 – Management

<table>
<thead>
<tr>
<th>Reference range</th>
<th>&lt; 40 years</th>
<th>40 - 49 years</th>
<th>50 - 59 years</th>
<th>60 - 69 years</th>
<th>≥ 70 years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt; 1.40 µg/L</td>
<td>&lt; 2.00 µg/L</td>
<td>&lt; 3.89 µg/L</td>
<td>&lt; 5.40 µg/L</td>
<td>&lt; 6.22 µg/L</td>
</tr>
</tbody>
</table>

Source: Roche Cobas® Total PSA kit insert 04-2015, V12.0
Guidance

Prostate cancer risk management programme: overview

From: Public Health England
First published: 1 January 2015
Last updated: 23 March 2016, see all updates

This document explains the Prostate Cancer Risk Management Programme (PCRMP), PSA testing and evidence against a national screening programme.

The NHS Prostate Cancer Risk Management Programme (PCRMP) provides GPs and primary care professionals with information to counsel asymptomatic men aged 50 and over who ask about prostate specific antigen (PSA) testing for prostate cancer.

The PCRMP, revised and updated in March 2016, includes:

- full evidence document for GPs
- summary information sheet for GPs
- summary information sheet for men aged 50 and over

NHS Choices also has further information that men may find helpful.

The PSA test measures the level of PSA in a man’s blood. It is the most common initial test for men who are worried about prostate cancer.
PSA testing and prostate cancer patient pathway

Consultation in primary care

No PSA test → Informed choice

PSA test

PSA in usual range
- Low risk of prostate cancer
- Refer to specialist only if there are other concerns

PSA level raised
- Age: 50-69
- PSA value: ≥3.0 ng/ml
  - Refer to specialist
  - Informed choice

No cancer diagnosed → Prostate biopsy
## Case 4 – Management

<table>
<thead>
<tr>
<th>Reference range</th>
<th>PSA Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 40 years</td>
<td>&lt; 1.40 μg/L</td>
</tr>
<tr>
<td>40 - 49 years</td>
<td>&lt; 2.00 μg/L</td>
</tr>
<tr>
<td>50 - 59 years</td>
<td>&lt; 3.88 μg/L</td>
</tr>
<tr>
<td>60 - 69 years</td>
<td>&lt; 5.40 μg/L</td>
</tr>
<tr>
<td>≥ 70 years</td>
<td>&lt; 6.22 μg/L</td>
</tr>
</tbody>
</table>

Source: Roche Cobas® Total PSA kit insert 04-2015, V12.0

The recommended referral value in men aged 50-69 is ≥ 3.0 ng/mL (≥ 3.0 μg/L).

Source:
- NICE CKS Prostate Cancer [NICE, August 2013]
Case 4 – Management

• So refer him then?
Case 4 – Management

NOT Formal guidance, but often advised:
• If borderline raised, consider repeating
  – e.g. after 6 weeks
  – Ensure all “rules” followed for a PSA test

• Although 2-week referral, very rarely that urgent
Guidance

Prostate cancer risk management programme: overview

From: Public Health England
First published: 1 January 2015
Last updated: 29 March 2016, see all updates

This document explains the Prostate Cancer Risk Management Programme (PCRMP), PSA testing and evidence against a national screening programme.

The NHS Prostate Cancer Risk Management Programme (PCRMP) provides GPs and primary care professionals with information to counsel asymptomatic men aged 50 and over who ask about prostate specific antigen (PSA) testing for prostate cancer.

The PCRMP, revised and updated in March 2016, includes:

- full evidence document for GPs
- summary information sheet for GPs
- summary information sheet for men aged 50 and over

NHS Choices also has further information that men may find helpful.

The PSA test measures the level of PSA in a man’s blood. It is the most common initial test for men who are worried about prostate cancer.
Advising well men aged 50 and over about the PSA test for prostate cancer: information for GPs

This Prostate Cancer Risk Management Programme (PCRM) sheet helps GPs give clear and balanced information to asymptomatic men who ask about prostate specific antigen (PSA) testing. The PSA test is available free to any well man aged 50 and over who requests it.

GPs should use their clinical judgement to manage symptomatic men and those aged under 50 who are considered to have higher risk for prostate cancer.

Prostate cancer
Each year in the UK about 47,000 men are diagnosed with prostate cancer and about 11,000 die from the disease. The most common age of diagnosis is 65 to 79. Men are at higher risk if they:
- have a family history of prostate cancer
- are of black ethnic origin – lifetime risk 1 in 4 compared to 1 in 8 for white men
- are overweight or obese (specifically for advanced prostate cancer)

Slow-growing tumours are common and may not cause any symptoms or shorten life. Some tested men may therefore face unnecessary anxiety, medical tests and treatments with side-effects.

PSA test
The test aims to detect localized prostate cancer when treatment can be offered that may cure cancer or extend life. It is not usually recommended for asymptomatic men with less than 10 years’ life expectancy.

Evidence suggests PSA screening could reduce prostate-cancer related mortality by 21%.
About 3 in 4 men with a raised PSA level (≥3mg/ml) will not have cancer. The PSA test can also miss about 15% of cancers.

Before a PSA test men should not have:
- an active urinary infection
- ejaculated in previous 48 hours
- exercised vigorously in previous 48 hours
- had a prostate biopsy in previous 6 weeks.

When taking blood:
- ensure specimen will reach laboratory in time for serum to be separated within 18 hours
- send samples to laboratories taking part in UK National External Quality Assurance Service

Digital rectal examination (DRE)
DRE allows assessment of the prostate for signs of prostate cancer (a hard gland, sometimes with palpable nodules) or benign enlargement (smooth, firm, enlarged gland). A gland that feels normal does not exclude a tumour.

Biopsy
A biopsy can diagnose prostate cancer at an early stage when a cure may be possible.
About 2 out of 5 men describe biopsy as painful. The most common complications (8 out of 10 men) are bleeding and infections. Most men experience blood in urine and semen after biopsy.
Some prostate cancers will be missed at biopsy (up to 1 in 5 men). If the biopsy is negative, follow-up and additional biopsies may be needed.

Management and treatment
Some men may benefit from treatment for localized prostate cancer. There is no clear evidence as to the best treatment option for localized prostate cancer.
The main treatment options are:
- active surveillance
- watchful waiting
- radical prostatectomy (open, laparoscopic or robotically assisted laparoscopic)
- external beam radiotherapy (EBRT)
- brachytherapy (low and high dose rate)

There are important quality of life differences between each option. The options available depend on the stage of disease, the man’s age and general health. Active surveillance involves repeat PSA testing and biopsies. Surgery and radiotherapy may offer the possibility of a cure but can have significant side-effects.

See patient information sheet for summary of the potential benefits and harms of PSA testing.
Case 5 – history

• 66 year-old on ‘combination therapy’ (tamsulosin and finasteride) for 3 years, LUTS well controlled
• PSA prior to treatment was 2.1, dropped to 1.0 after 6 months on treatment
• Over the last 9 months, mild worsening of symptoms
• PSA increased a little from 0.9 to 2.2
Case 5 – question

• What do you tell him about his PSA?
• What would you do now?
Case 5 – examination

• You examine his prostate: nothing worrying
Case 5 – management

• Worrying features:
  – Rate of rise of PSA
  – Doubling PSA on finasteride gives a raised result
  – Any rise on finasteride should be treated with more suspicion than normal

• Given the **rate of rise** in his PSA you refer for a specialist opinion
Case 5 – management

- The urologist notes a slightly firm left lobe
- MRI suspicious, has biopsy of the prostate
- A Gleason 8 (moderately aggressive) prostate cancer is diagnosed
- Treated with radical radiotherapy
Case 5 – learning points

• Prostate cancer can be present with a “normal” PSA

• PSA results for men on 5-ARIs (treated for >6 months) need to be ~doubled to compare with age-specific ranges

• PSA will slowly rise in men with BPH, but generally at a velocity of < 0.5-0.75 ng/ml per year

• Here, rise of 1.3 in 9 months: very suspicious
10. PSA history and a rising PSA (whilst still under the referral threshold) should be taken into consideration when deciding whether to refer to secondary care.
Case 6 – history

• A 46 year-old African-Caribbean man asks to be tested for prostate cancer
• He has no 1\textsuperscript{st}-degree positive family history
• No troublesome LUTS

• What do you discuss with him?
Case 6 – Mx and learning

• Should enable him to make a shared decision
• 2-3x risk from ethnicity
• Some guidelines do support testing in 40s
9. Asymptomatic men at higher than average risk of prostate cancer who have a PSA test between the ages of **45 and 49** should be referred for further investigations if their PSA level is higher than **2.5ng/ml**.
Case 6 – Next..

- PSA comes back at 1.1
- What do you advise next?
Case 6 – Next..

- His result is in upper range for this age
- Should repeat in 2-4 years

- (If it was <1, repeat in approx 10 yrs, mid-50s)
Case 6

• How would you approach this if he was only 42 years old?
PCUK Consensus Statements

12. Asymptomatic men over 40 should consider a single “baseline” PSA test to help predict their future prostate cancer risk.

• If the PSA level is above the age-specific median value, they should be considered at higher than average risk of prostate cancer and should be encouraged to be re-tested in the future.

• (The age-specific MEDIAN value for men aged 40-49 years is 0.7ng/ml)